Tenaya to deploy $92M series B to develop heart disease platforms in parallel

For its $92 million series B round, Tenaya sought a syndicate willing to invest enough that the company could advance heart disease programs from multiple modalities toward the clinic simultaneously.

The company's regenerative medicine and gene therapy programs could enter first-in-human studies as soon as late 2021, CEO Faraz Ali told BioCentury...